Carregant...
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.
Guardat en:
| Publicat a: | J Hematol Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4545857/ https://ncbi.nlm.nih.gov/pubmed/26208852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0192-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|